Regulation


<div class="articleContainer">
<div class="articleWrapper">
<div class="articleContent">
<h1 class="text title" doc-editable="text" data-component-id="doc-1ef7l320d0">Pricing the uncertainty in expedited therapies</h1><h2 class="title-bottom webtitle" doc-editable="title" data-component-id="doc-1ef7l34r60">How new ideas about pay for performance aim to temper uncertainties, and controversies, about accelerated approvals</h2><div class="byline ng-tns-c17-4 ng-star-inserted" data-component-id="doc-1ef7l3fol0">
    <span class="ng-tns-c17-4" doc-editable="text">By Steve Usdin, Washington Editor</span>
</div><div class="date" data-component-id="doc-1ef7l3l440">
  <span class="byline" doc-editable="text"></span>
</div></div></div></div>


Biogen Inc.

Sarepta Therapeutics Inc.

Duke University

Massachusetts Institute of Technology

Pricing the uncertainty in expedited therapies

How new ideas about pay for performance aim to temper uncertainties, and controversies, about accelerated approvals.

How new ideas about pay for performance aim to temper uncertainties, and controversies, about accelerated approvals

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

The BioCentury Show

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><br/><center><span style="font-size:1.75rem;font-weight:500;">Access this Article</span></center>